Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Quidel Sofia™ 2 SARS Antigen Fluorescent Immunoassay (FIA)

Uses immunofluorescence-based lateral flow technology in a sandwich design for qualitative detection of nucleocapsid protein from SARS-CoV-2. Provides automated and objective results in 15 minutes, allowing for testing of patients suspected of COVID-19/2019-nCoV in near-patient testing environments.

Specifications

Clia Complexity Waived
Packaging Quantity 25 Tests/Pk. or 300 Tests/Cs.
Test Time 15 minutes
View More Specs

Alert:

Order eligibility is based upon executed contractual agreement.


Products 2
Catalog Number Mfr. No. Sample Type Price Quantity & Availability  
Catalog Number Mfr. No. Sample Type Price Quantity & Availability  
23-043-153
View Documents
Quidel
20383
Nasopharyngeal Pack of 25 for $875.00
Case of 12 PK for $10,500.00
N/A
Due to product restrictions, please to purchase or view availability for this product.
23-043-151
View Documents
Quidel
20374
Direct or VTM: Nasal swab, nasopharyngeal swab Pack of 25 for $875.00
Case of 12 PK for $10,500.00
N/A
Due to product restrictions, please to purchase or view availability for this product.
Description

Description

  • Rapid results in 15 minutes to support efficient dispositioning of patients
  • Objective, accurate results without cross-reactivity to seasonal coronaviruses
  • Dual work modes adjust to volume fluctuations and allows for significant throughput and batching of samples in READ NOW Mode
  • Seamless test workflow follows a similar format to CLIA-waived Sofia and Sofia 2 assays
  • Virena provides automated tracking, data capture, government reporting, and exclusive disease mapping.
  • Fluorescent technology with automated read eliminates the subjectivity of a visual result
  • All necessary components included in kit, ready for use for swab procedure
  • Self-contained Test Cassette that is clean, easy to use and dispose of
Note:  CLIA Complexity is waived. fda.gov: The settings in which an EUA-authorized test may be used are described in the Letter of Authorization. As discussed in the Guidance for Industry and Other Stakeholders: Emergency Use Authorization of Medical Products and Related Authorities, when the FDA authorizes tests for use at the point of care (including SARS-CoV-2 point of care test systems) under an EUA, such tests are deemed to be CLIA waived tests. Accordingly, for the duration of the emergency declaration, such tests can be performed in a patient care setting that is qualified to have the test performed there as a result of operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. 

Specifications

Specifications

Waived
25 Tests/Pk. or 300 Tests/Cs.
15 minutes
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit